Mahmoud Aljurf (@aljurf100) 's Twitter Profile
Mahmoud Aljurf

@aljurf100

Hematology & HSCT Program. King Faisal Specialist Hospital & Research Center. Riyadh- Saudi Arabia. #bmtsm #leusm #BMFSM #lymsm

ID: 835587356812062720

calendar_today25-02-2017 20:28:45

8,8K Tweet

2,2K Followers

40 Following

Carmelo Gurnari (@carmelogurnari) 's Twitter Profile Photo

Overexcited for this piece out in The Lancet Haematology 👉 a huge collaboration on behalf of the CMWP of the The EBMT led by DrDonalMcLornan and an incredible global panel of experts: how to deal with germline predisposition in MDS undergoing HSCT. authors.elsevier.com/c/1h~Ie_rV3GEO…

Andrea Zimmer, MD (@andreajzimmer) 's Twitter Profile Photo

Happy to announce that the TxID Special Edition on infections in patients with heme malignancies and recipients of cellular therapies is now available! Sincere thanks to all the authors for their contributions--lots of high-yield, timely information in here! Gabrielle Haeusler

Mahmoud Aljurf (@aljurf100) 's Twitter Profile Photo

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation - The Lancet Haematology thelancet.com/pdfs/journals/…

Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 (@bllphd) 's Twitter Profile Photo

NEW from Rahul Banerjee, MD, FACP David Maloney & colleagues: Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic Blood Advances Immortal time bias = if pts don't live longer (thanks to CAR T), secondary malignancy won't be observed #cancer #immunotherapy

NEW from <a href="/RahulBanerjeeMD/">Rahul Banerjee, MD, FACP</a> David Maloney &amp; colleagues: Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic <a href="/BloodAdvances/">Blood Advances</a> Immortal time bias = if pts don't live longer (thanks to CAR T), secondary malignancy won't be observed 
#cancer #immunotherapy
The Lancet Haematology (@thelancethaem) 's Twitter Profile Photo

NEW: Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of The EBMT #bmtsm #GVHD thelancet.com/journals/lanha…

NEW: Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of <a href="/TheEBMT/">The EBMT</a> 
#bmtsm #GVHD
thelancet.com/journals/lanha…
Blood Advances (@bloodadvances) 's Twitter Profile Photo

Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies #genetherapy

Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies
#genetherapy
Transplantation and Cellular Therapy Journal (@astct_journal) 's Twitter Profile Photo

The meta-analysis of real-world studies of axi-cel versus tisa-cel in relapsed/refractory DLBCL finds that axi-cel significantly improves responses and progression-free survival, while tisa-cel significantly reduces higher-grade CRS and neurotoxicity. ow.ly/Q1sx50SNJ6z

The meta-analysis of real-world studies of axi-cel versus tisa-cel in relapsed/refractory DLBCL finds that axi-cel significantly improves responses and progression-free survival, while tisa-cel significantly reduces higher-grade CRS and neurotoxicity. ow.ly/Q1sx50SNJ6z
Saudi Arabia Chapter of ACP (@acpsaudiarabia) 's Twitter Profile Photo

Join us at the annual Saudi Liver Meeting 2024! Visit our booth to learn more about ACP membership and explore the latest advancements in liver health. See you there! 🩺🤩 زورونا في مؤتمر الكبد السنوي الذي تنظمه الجمعية السعودية لأمراض وزراعة الكبد للاطلاع على أحدث التطورات في

Mehdi Hamadani, MD (@medihumdani) 's Twitter Profile Photo

With increasing pola using in frontline, is CD19 bridge to CD19 CAR possible? We think so, with CD19 directed ADC loncastuximab in CIBMTR database #lymsm onlinelibrary.wiley.com/doi/10.1002/jh…

CIBMTR (@cibmtr) 's Twitter Profile Photo

Severe aplastic anemia (SAA) is a disease where the bone marrow doesn’t make enough blood cells. #BMT can cure SAA, but it also can have serious effects on the skin, eyes, digestion, memory, and more. Read more about this BMT CTN study: cibmtr.org/Files/Patient-…

Severe aplastic anemia (SAA) is a disease where the bone marrow doesn’t make enough blood cells. #BMT can cure SAA, but it also can have serious effects on the skin, eyes, digestion, memory, and more. Read more about this <a href="/BMTCTN/">BMT CTN</a> study: cibmtr.org/Files/Patient-…
The EBMT (@theebmt) 's Twitter Profile Photo

📣 We are proud to announce the new open-access EU CAR-T Handbook, now available in a digital format on our website. GoCART_Coalition European Hematology Association This updated version includes new developments in CAR-T according to the latest clinical data and regulatory advancements.

📣 We are proud to announce the new open-access EU CAR-T Handbook, now available in a digital format on our website. <a href="/GoCARTcoalition/">GoCART_Coalition</a> <a href="/EHA_Hematology/">European Hematology Association</a>

This updated version includes new developments in CAR-T according to the latest clinical data and regulatory advancements.
The EBMT (@theebmt) 's Twitter Profile Photo

💡 Have you seen this recent publication in Bone Marrow Transplantation? 📰 Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice

Nausheen Ahmed MD (@nausheenahmedmd) 's Twitter Profile Photo

Had a wonderful experience listening to Mehdi Hamadani, MD talk in #Kansas! Simple, crisp, and straight to the point. Always a pleasure to hear him speak! #Auto role in #lymphoma

Had a wonderful experience listening to <a href="/MediHumdani/">Mehdi Hamadani, MD</a> talk in #Kansas! Simple, crisp, and straight to the point. Always a pleasure to hear him speak! #Auto role in #lymphoma
CAR T day (@cartday_) 's Twitter Profile Photo

🌟 Join us in Lille for CAR T day, the 9th International Symposium on CAR T cells🌟 From September 11-12, 2025, the #CARTday will have the immense pleasure of welcoming you to one of France's most iconic cities: Lille! ✨ Why choose Lille? A center of excellence in oncology:

CAR T day (@cartday_) 's Twitter Profile Photo

🤔 Did you know? 💡CAR T cell therapy (Chimeric Antigen Receptor - T) is a groundbreaking cellular immunotherapy strategy, rapidly advancing to fight cancer. CAR T cells are genetically modified T lymphocytes designed to recognize and destroy cancer cells. 👁️‍🗨️ Here's how it